A comprehensive review on the dynamics of protein kinase CK2 in cancer development and optimizing therapeutic strategies

被引:0
|
作者
Ghani, Muhammad Usman [1 ,2 ]
Shi, Junbo [1 ,2 ]
Du, Yi [1 ,2 ]
Zhong, Liping [4 ]
Cui, Hongjuan [1 ,2 ,3 ]
机构
[1] Southwest Univ, Med Res Inst, Chongqing 400715, Peoples R China
[2] Southwest Univ, State Key Lab Resource Insects, Chongqing 400715, Peoples R China
[3] Jinfeng Lab, Chongqing 401329, Peoples R China
[4] Guangxi Med Univ, State Key Lab Targeting Oncol, Nanning 530021, Guangxi, Peoples R China
基金
美国国家科学基金会;
关键词
CK2; Signal transduction; Apoptosis; Hallmark of cancer; Therapy; NF-KAPPA-B; BIOLOGICAL EVALUATION; SIGNALING PATHWAY; CELLS; DEGRADATION; ACTIVATION; CK2-ALPHA; TARGETS; RNAI;
D O I
10.1016/j.ijbiomac.2024.135814
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinase 2 (CK2) is an enzyme ubiquitously present and exhibits extensive kinase activity. It has been strongly linked to tumor progression through the abnormal phosphorylation of key proteins. Research has consistently demonstrated that CK2 is deregulated in various cancer types, with enhanced protein expression and nuclear distribution in tumor cells. CK2 plays a crucial role in a complex network that promotes cell infiltration, migration, proliferation, apoptosis, and cancer progression through multiple pathways, including PI3K/AKT, JAK2/STAT3, ATF4/CDKN1, and HSP90/Cdc37. In addition to its role in cancer growth, there is mounting evidence that CK2 may also affect the immunological dynamics of cancer by altering immune cell functions within the tumor microenvironment, thus facilitating tumor immune evasion. Recent research has increasingly focused on CK2, recognizing it as a therapeutic objective for oncological interventions. This review will critically examine the structure and signaling pathways of CK2, highlighting the significance of further research aimed at enhancing our understanding of the CK2 machinery. Finally, we conclude by refining therapeutic options, notably transitioning from non-pharmacological techniques to strategic CK2 inhibitor use. This development shortens the path to the desired outcome, establishing a pioneering standard in cancer therapy.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Protein kinase CK2 in human diseases
    Guerra, Barbara
    Issinger, Olaf-Georg
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (19) : 1870 - 1886
  • [42] Protein kinase CK2 and cell polarity
    Alexandre Deshière
    Nathalie Theis-Febvre
    Véronique Martel
    Claude Cochet
    Odile Filhol
    Molecular and Cellular Biochemistry, 2008, 316 : 107 - 113
  • [43] Cellular regulators of protein kinase CK2
    Montenarh, Mathias
    CELL AND TISSUE RESEARCH, 2010, 342 (02) : 139 - 146
  • [44] How Druggable Is Protein Kinase CK2?
    Cozza, Giorgio
    Bortolato, Andrea
    Moro, Stefano
    MEDICINAL RESEARCH REVIEWS, 2010, 30 (03) : 419 - 462
  • [45] Protein kinase CK2 as a "drugable" target
    Pinna, LA
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 28 : S5 - S6
  • [46] Protein Kinase CK2 Regulates B Cell Development and Differentiation
    Wei, Hairong
    Yang, Wei
    Hong, Huixian
    Yan, Zhaoqi
    Qin, Hongwei
    Benveniste, Etty N.
    JOURNAL OF IMMUNOLOGY, 2021, 207 (03): : 799 - 808
  • [47] Protein kinase CK2 as a druggable target
    Sarno, Stefania
    Pinna, Lorenzo A.
    MOLECULAR BIOSYSTEMS, 2008, 4 (09) : 889 - 894
  • [48] Protein kinase CK2 and cell polarity
    Deshiere, Alexandre
    Theis-Febvre, Nathalie
    Martel, Veronique
    Cochet, Claude
    Filhol, Odile
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2008, 316 (1-2) : 107 - 113
  • [49] Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity
    Odile Filhol
    Sofia Giacosa
    Yann Wallez
    Claude Cochet
    Cellular and Molecular Life Sciences, 2015, 72 : 3305 - 3322
  • [50] Protein kinase CK2: a challenge to canons
    Pinna, LA
    JOURNAL OF CELL SCIENCE, 2002, 115 (20) : 3873 - 3878